Literature DB >> 21853271

Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Takehiko Mori1, Jun Kato2,3, Akiko Yamane2,3, Yoshinobu Aisa2, Yusuke Kawata4, Mayu Ichimura4, Chiaki Tsuneyama4, Tomoko Yashima4, Yoko Ogawa5, Kazuo Tsubota5, Naoyuki Shigematsu6, Takayuki Shimizu2, Shinichiro Okamoto2.   

Abstract

We previously reported a high incidence of kerato-conjunctivitis in patients receiving high-dose cytarabine following total body irradiation (TBI) as a conditioning for hematopoietic stem cell transplantation (HSCT) even on prophylaxis with topical corticosteroid. This study aimed to evaluate whether addition of eye rinse, which was designed to remove cytarabine from ocular surface, further reduces the incidence of kerato-conjunctivitis in the same setting. Seventy-six patients receiving cytarabine at a dose of 3 g/m(2) every 12 h for 4 days after receiving TBI (12 Gy) as conditioning for HSCT were evaluated. All patients received betamethasone sodium phosphate eye drops. Twenty-three patients were further instructed to rinse their eyes with sterile saline every 10-15 min during and for two additional hours after the completion of each cytarabine infusion. Among 23 patients with eye rinse, Grades 2-3 and 1-3 kerato-conjunctivitis were observed in 4 (17.4%) and 5 patients (21.7%), respectively. These incidences were significantly lower than those [35 (66.0%) and 41 (77.4%)] observed in 53 patients without eye rinse (P < 0.001 and P < 0.00001, respectively). These results strongly suggest that eye rinse effectively reduces the incidence and severity of cytarabine-induced kerato-conjunctivitis in HSCT recipients who receive high-dose cytarabine following TBI.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21853271     DOI: 10.1007/s12185-011-0912-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  18 in total

1.  Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.

Authors:  T Mori; Y Aisa; A Yokoyama; T Nakazato; R Yamazaki; T Shimizu; A Mihara; J Kato; R Watanabe; N Takayama; Y Ikeda; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2007-01-15       Impact factor: 5.483

Review 2.  Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma.

Authors:  J G Letschert; D González González; J Oskam; L Koornneef; J D van Dijk; R Boukes; J Bras; P van Heerde; H Bartelink
Journal:  Radiother Oncol       Date:  1991-09       Impact factor: 6.280

3.  Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.

Authors:  H M Lazarus; M E Hartnett; M D Reed; B F Murphy; J H Lass
Journal:  Am J Ophthalmol       Date:  1987-11-15       Impact factor: 5.258

4.  Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma.

Authors:  E M Bessell; J M Henk; R A Whitelocke; J E Wright
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

Review 5.  Ocular toxicity and cancer chemotherapy. A review.

Authors:  T al-Tweigeri; J M Nabholtz; J R Mackey
Journal:  Cancer       Date:  1996-10-01       Impact factor: 6.860

6.  Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.

Authors:  Takehiko Mori; Yoshinobu Aisa; Reiko Watanabe; Rie Yamazaki; Jun Kato; Takayuki Shimizu; Naoyuki Shigematsu; Atsushi Kubo; Tomonaru Yajima; Toshifumi Hibi; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

7.  Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.

Authors:  Paola Matteucci; Carmelo Carlo-Stella; Massimo Di Nicola; Michele Magni; Anna Guidetti; Maddalena Marchesi; Alessandro Massimo Gianni
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

8.  Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Kaori Hasegawa; Ai Okabe; Natsuki Tsujimura; Yusuke Kawata; Tomoko Yashima; Naoko Kobayashi; Sakiko Kondo; Yoshinobu Aisa; Jun Kato; Kazuyuki Tsunoda; Tetsuo Nagai; Taneaki Nakagawa; Naoyuki Shigematsu; Atsushi Kubo; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2008-10-30       Impact factor: 2.490

9.  Recombinant human glycosylated granulocyte colony-stimulating factor (rhG-CSF)-combined regimen for allogeneic bone marrow transplantation in refractory acute myeloid leukemia.

Authors:  S Takahashi; S I Okamoto; N Shirafuji; K Ikebuchi; K Tani; M Shimane; T Matsudaira; S Irie; T Tsuruta; E Matsuishi
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

10.  Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine.

Authors:  J H Lass; H M Lazarus; M D Reed; R H Herzig
Journal:  Am J Ophthalmol       Date:  1982-11       Impact factor: 5.258

View more
  1 in total

1.  N-acetylcysteine supplementation reduces oxidative stress for cytosine arabinoside in rat model.

Authors:  Yasemin Isik Balci; Semra Acer; Ramazan Yagci; Vural Kucukatay; Hakan Sarbay; Kerem Bozkurt; Aziz Polat
Journal:  Int Ophthalmol       Date:  2016-05-23       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.